Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxidectin vs Ivermectin for Onchocerciasis Control (EKAIO)
NCT07145736Phase 4Recruiting
- Sponsor
- The Kirby Institute
- Start
- Aug 2025
- Primary completion
- Mar 2029
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of moxidectin in onchocerciasis, ascariasis, trichuriasis and 2 more (2 arms), sponsored by The Kirby Institute. Primary endpoint: Prevalence of Onchocerca volvulus microfilariae at 36 months. Started Aug 2025; status: recruiting.
02
Drugs
moxidectin
03
Conditions
onchocerciasisascariasistrichuriasishookworm infectionscabies
Beyond the preview
Go deeper on NCT07145736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145736.